The Holistic prevention, management and treatment of Polycystic Ovarian Syndrome: The Insulin resistance improvement and/or anti metabolic syndrome herb: Astragalus

By Kyle J. Norton
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                    Polycystic Ovarian Syndrome

Polycystic Ovarian Syndrome is defined as endocrinologic diseases among reproductive-age women caused by undeveloped follicles clumping on the ovaries that interferes with the function of the normal ovaries associated with a high risk for metabolic disorder(1) as resulting of enlarged ovaries(2), leading to hormone imbalance(excessive androgen and anti-müllerian hormone (AMH) )(1)(3)(4)(5), induced Hirsutism(6)(7), reproductive disorder(10(12)), risks of type 2 diabetes(9)(10)(11), metabolic syndrome(10)(12) and early cardiovasular disease(8)(13), acne(10)(14), endometrial cance(18)(19),weight gain and obesity(15)(16)(17). The syndrome effects over 5% of women population or 1 in 20 women.
Unfortunately, according to studies, women with PCOs after the reproductive age, are associated to  continuously increase risk of type II diabetes, with no increasing altered glucose tolerance(20), CVD and hypertension(21).

          The prevention and management  In Herbal Medicine

Polycystic ovary syndrome (PCOS) is unpreventable in Western medicine. Early diagnosis and treatment  may reduce risk of its complications, including infertility, metabolic syndrome, obesity, diabetes, cardiovascular diseases, stroke, etc.
        Reduce fat intake less than 30% of total calories with a low proportion of saturated fat and high in fiber from predominantly low-glycaemic-index-carbohydrate foods for patients with PCOs(827a). Calorie intake should be distributed between several meals per day with restricted intake of snacks and drinks(828).

 The Insulin resistance improvement and/or anti metabolic syndrome herbs


Astragalus (Astragalus membranaceus)(1045)
Huang Qi or Bei Qi is also known as Astragalus root. The sweet herb has been used as diuretic agent and to lower blood pressure, increase blood pressure, lessens proteinuria, improve endurance, protect liver function, regulate blood sugar, etc. as it tonifies Qi, raises Yang, strengthens the Defensive-Qi and the Exterior, expels toxins, etc. by enhancing the functions of lung and spleen channels(1045).

Ingredients
1. Astragaloside I,
2. Astragaloside II,
3. Daucosterol,
3. Beta-sitosterol,
4. Palmitic acid
5. Astragalus saponin A,B,C
6. Astramenbrangenin
7. Kumatakenin,
8. Choline,
9. Betaine,
10. Folic acid
11. Calyxosin,
12. Formononetin,
13. Cycloastragenol,
14. Astragaloside III,IV
15. Antibacterial ingredient,
16. L-3-hydroxy-9-methoxpterocarpan
17. Etc.

Epidemiological studies showed that stragalus polysaccharides (APS) ameliorates insulin resistance(1046)(1047) (IR) in rat cells and to elucidate the associated mechanisms, including increasing adiponectin secretion and reducing IL-6 secretion(1046), decreasing myostatin expression(1047), improving beta cell function(1049), regulating insulin signaling in insulin-resistant skeletal muscle(1047)(1048). insulin resistance related mRNA expression(1049), etc.
In metabolic syndrome, including increased body weight(1050), mild hypertension(1050), hyper insulinemia(1050), hyper triglyceridemia(1050), impaired glucose tolerance(1050)(1053) and impaired endothelium-dependent vasorelaxation(1050)(1051)(1052), astragaloside IV, a major constituent found in astragalus showed effectively in ameliorating metabolic syndrome(1050)(1052), probably through its antioxidant(1051), inhibition of abnormal TNF-alpha-induced intracellular free Ca(2+) accumulation in endothelial cells(1052), decreasing the elevated expression and activity in the skeletal muscles(1053).

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months   

References
(1) Adiposity and metabolic dysfunction in polycystic ovary syndrome by Sam S.(PubMed)
(2) A "kiss" before conception: triggering ovulation with kisspeptin-54 may improve IVF by Young SL.(PubMed)
(3.) Androgen hyperfunction and excessive heterosexual hair growth in women, with special attention to the polycystic ovarian syndrome by Lunde O¹.(PubMed)
(4) Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome by Du DF¹, Li XL, Fang F, Du MR.(PubMed)
(5) [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].[Article in Bulgarian] by Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.(PubMed)
(6) [Current opinions on the etiology and pathophysiology of hirsutism].[Article in Polish] by Krysiak R¹, Kedzia A, Okopień B.(PubMed)
(7) The clinical evaluation of hirsutism by Somani N¹, Harrison S, Bergfeld WF.(PubMed)
(8) Polycystic ovary syndrome and insulin: our understanding in the past, present and future by Mayer SB¹, Evans WS, Nestler JE.(PubMed)
(9) Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome by Dogan BA¹, Arduc A², Tuna MM¹, Karakılıc E¹, Dagdelen I¹, Tutuncu Y¹, Berker D¹, Guler S¹.(PubMed)
(10) Approach to the patient: contraception in women with polycystic ovary syndrome by Yildiz BO¹.(PubMed)
(11) Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women by Talbott EO¹, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ.(PubMed)
(12) Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities by Figurová J¹, Dravecká I, Javorský M, Petríková J, Lazúrová I.(PubMed)
(13) Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis by Thethi TK¹, Katalenich B², Nagireddy P³, Chabbra P⁴, Kuhadiya N⁵, Fonseca V¹.(PubMed)
(14) Acne in hirsute women by Lumezi BG¹, Pupovci HL¹, Berisha VL¹, Goçi AU², Gerqari A³.(PubMed)
(15) Obesity and polycystic ovary syndrome by Naderpoor N¹, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ.(PubMed)
(16) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan by Teede H¹, Deeks A, Moran L.(PubMed)
(17) Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome. by Whigham LD¹, Butz DE², Dashti H³, Tonelli M³, Johnson LK¹, Cook ME², Porter WP⁴, Eghbalnia HR⁵, Markley JL⁶, Lindheim SR⁷, Schoeller DA⁸, Abbott DH⁹, Assadi-Porter FM¹⁰.(PubMed)
(18) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis by Barry JA¹, Azizia MM¹, Hardiman PJ².(PubMed)
(19) Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study by Gottschau M¹, Kjaer SK², Jensen A¹, Munk C¹, Mellemkjaer L³.(PubMed)
(20) Polycystic ovary syndrome: metabolic consequences and long-term management by Carmina E¹.(PubMed)
(21) Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype by Armeni E¹, Stamatelopoulos K, Rizos D, Georgiopoulos G, Kazani M, Kazani A, Kolyviras A, Stellos K, Panoulis K, Alexandrou A, Creatsa M, Papamichael C, Lambrinoudaki I.(PubMed)
(827a) Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management by Farshchi H, Rane A, Love A, Kennedy RL(PubMed)
(828) The optimal diet for women with polycystic ovary syndrome? by Marsh K, Brand-Miller J.(PubMed) 
(1045) Huang Qi(Complementary and Alternative Healing University)
(1046) Amelioration of insulin resistance in rat cells by Astragalus polysaccharides and associated mechanisms by Liu H¹, Bai J², Weng X³, Wang T³, Li M¹.(PubMed)
(1047) Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: involvement of ROS-ERK and NF-κB pathways by Liu M¹, Qin J², Hao Y³, Liu M⁴, Luo J⁵, Luo T⁴, Wei L⁶.(PubMed)
(1048) Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle by Liu M¹, Wu K, Mao X, Wu Y, Ouyang J.(PubMed)
(1049) A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice by Gao LH¹, Liu Q¹, Liu SN¹, Chen ZY¹, Li CN¹, Lei L¹, Sun SJ¹, Li LY¹, Liu JL¹, Shen ZF².(PubMed)
(1050) [Effects of Astragalus membranaceus and Potentilla discolor mixture on insulin resistance and its related mRNA expressions in KKAy mice with type 2 diabetes].[Article in Chinese] by Zhang DM¹, Lou LX, Wu AM, Lü XY, Hu ZJ, Zhang YH, Liu HF.(PubMed)
(1051) Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation by Qiu LH¹, Xie XJ, Zhang BQ.(PubMed)
(1052) Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro by Xu ME¹, Xiao SZ, Sun YH, Ou-Yang Y, Zheng XX.(PubMed)
(1053) Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B by Wu Y¹, Ou-Yang JP, Wu K, Wang Y, Zhou YF, Wen CY.(PubMed)